Thursday, November 09, 2017 9:22:59 AM
"We continue to believe investors are overlooking the
risk-reduced growth prospects in each two pillars of the business,..."
Piper Jaffray
C O M PA N Y N O T E
O c t o b e r 1 6 , 2 0 1 7
Halozyme Therapeutics, Inc. (HALO) Overweight
Enhanced Conviction on ENHANZE Clearly Becoming a Value Enhancing Platform
PRICE: US$17.47
TARGET: US$29.00
Charles C. Duncan, PhD
Sr. Research Analyst, Piper Jaffray & Co.
Sarah R. Weber
Research Analyst, Piper Jaffray & Co.
Changes Previous Current
Rating — Overweight
Price Tgt US$26.00 US$29.00
CONCLUSION
We recently hosted Halozyme for investor meetings and came away with enhanced
conviction in the company's long-term ENHANZE strategy, as well as the potential of
PEGPH20 inclusive of but even beyond pancreatic cancer. We are raising our PT from
$26 to $29 in anticipation of value creation from ENHANZE progress (within current
collaborations and potentially from 1-2 new ones), plus several Phase I/II PEGPH20 combo
studies in the next 12-18 months. We continue to believe investors are overlooking the
risk-reduced growth prospects in each two pillars of the business, as well as the synergies
between them, with more details on our outlook below. In advance of increasingly visible
clinical and commercial progress for Halozyme, we reiterate OW.
• ENHANZE Momentum Building. We believe investors may be underestimating the
long-term value from ENHANZE. Specifically, we see three factors as driving this value.
First, the Rituxan Hycela Ad Comm earlier this year clarified the regulatory path in
the eyes of current or potential ENHANZE partners. Second, we perceive growing
appreciation for ENHANZE products as not just supporting life cycle management, but
as driving true innovation in the form of meaningful patient/provider preferences and
potentially improved clinical outcomes. For example, the Phase I Darzalex SC study
demonstrated a significant improvement in administration times (multiple hour infusion
to minutes long injection) and a decrease in infusion reaction rates, all of which should
support compliance and outcomes, over time. Third, we believe the commercial value
proposition of an SC product is well suited for the EU, and more recently the US market,
in terms of cost savings for the increasingly cost-constrained system and, for individual
prescribers, a decreasing profit differential between IV and SC drugs in oncology. Please
see Exhibit 1 for a summary of ENHANZE products and progress we'll be tracking in
the next twelve months. Overall, we believe the above factors will lead to accelerated
progress within Halozyme's seven existing collaborations (Exhibit 2) and at least one
new high value collaboration in the next ~12-18 months.
• PEGPH20 - More than just PC. Following these recent meetings, we continue to believe
investors may be overlooking value creation from PEGPH20 in multiple solid tumor types.
On pancreatic cancer and relative to other recent attempts by other sponsors, we believe
this program is significantly risk reduced by the prospective, placebo controlled Phase II
dataset, mechanism which enhances SOC, and rationally selected patient group. Each of
these factors differentiates the PEGPH20 program from recent failures to translate Phase
II activity to positive Phase III results, in our view. We expect enrollment to complete in
1H18 to support a PFS interim in (if we had to hazard a timeline) 2019.
Beyond PC, also gleaned from the roadshow, we have a refreshed perspective on the potential
of PEGPH20 to enhance response rates to IO agents. Specifically, in animal models PEGPH20
increases the concentration of these drugs in the tumor by 40-80%, as well as increasing immune
cell infiltration of the tumor micro environment (TME). We also anticipate several updates from
one of the multiple combo trials (ongoing or about to start) approximately every six months for
the next two years - Exhibit 3. If demonstrated data is promising, these could support signing
further partnerships for capital efficient late-stage clinical development.
Model updates: Price Target to $29. Based on the above updates, today we are incrementally
reducing our discount rate on future ENHANZE royalty revenue streams from 12% to 10%.
In addition, we are adding in a $250M pipeline placeholder value for the IO combination
opportunities with PEGPH20. Finally, we are pushing first sales of PEGPH20 back to 2020 from
2019 to align with timelines for that study; enrollment is progressing as expected and our model
projection was likely somewhat aggressive on investigative site initiation timelines. Finally, we
believe the BMS up-front will hit the P+L during 4Q17 versus 3Q17, and are updating our model
accordingly. Overall, these changes result in a price target of $29 up from $26 - Exhibit 4.
Exhibit 1
Select ENHRANZE-Partnered Candidates We're Watching
Source: PJC Research
Exhibit 2
Progression of ENHANZE Collaborations
Roche Baxalta Pfizer Janssen AbbVie Lilly Bristol-Myers Roche
Source: Company Reports
Partner Target/Candidate Next Event Estimated Date
BMS Opdivo Phase I trial start 1H18
Janssen Darzalex Phase III trial start
4Q17 (Design posted on Clinicaltrials.gov
NCT03301220)
Lilly Anti IL-23 Update from recently initiated Phase I trial 2018
Roche
New, yet undisclosed target
announced Sept '17
Phase I start
1H18
Roche Perjeta Potential Phase III start 2018
Roche Rituxan Hycela (approved) US launch updates 2018 guidance 1Q18; 1H18 earnings
PEGPH20 Combo Study Catalysts
Source: PJC Research
Exhibit 4
Current $29 PT (Top) and Previous $26 PT (Bottom)
Source: PJC Research
Tumor Type Phase Combination Medication Next Event Our Estimated Date Sponsor
Pancreas III Abraxane + Gemcitabine Complete enrollment 1H18 Halozyme
PFS Interim 2019
Gastric Cancer I/II Keytruda
Initial dose-finding +
responder rates
4Q17/1Q18 Halozyme
NSCLC I/II Keytruda
Initial dose-finding +
responder rates
1H18 Halozyme
6 Tumor Basket including
pancreas + gastric
I/II Tecentriq Dose-finding updates 2H18/1H19 Roche
Gall bladder +
cholangiocarcinoma
Ib Tecentriq Open enrollment 4Q17 Halozyme
Breast Cancer I/II Halaven Updates on dose-finding 2H18/1H19 Eisai
Source: Company Reports, ClinTrials.gov
NPV NPV
(MM$) Per Share ($)
Roche royalties 999 6.66
PEGPH20 in PC 1,539 10.26
HyQ/HyQvia 195 1.30
1st PFE, JNJ, ABBV, & BMS 3,259 21.73
Other Income & Expenses (2,083) (13.89)
PEGPH20 Combo in Other Solid Tumors 250 1.7
Cash 380 2.5
Long-term debt (174) (1.2)
Total NPV 4,364 $29.09
NPV NPV
(MM$) Per Share ($)
Roche royalties 999 6.66
PEGPH20 (PC) 1,581 10.54
HyQ/HyQvia 195 1.30
1st PFE, JNJ, ABBV, & BMS 2,947 19.64
Other Income & Expenses (2,083) (13.89)
Cash 380 2.5
Long-term debt (174) (1.2)
Total NPV 3,844 $25.63
Halozyme Therapeutics, Inc. Page 4 of 7
Halozyme ($ in millions, except per share amounts) 2014 2015 1Q16A 2Q16A 3Q16A 4Q16A 2016A 1Q17A 2Q17A 3Q17E 4Q17E 2017E 1Q18E 2Q18E 3Q18E 4Q18E 2018E
Income Statement
Revenue
Product sales, net (Hylenex and bulk Roche and Baxter supply) 37.8 46.1 12.9 13.7 13.3 13.4 53.4 11.4 12.8 13.5 14.0 51.7 14.5 14.5 14.5 14.5 58.0
Royalties, PEGPH20 Revenues 9.4 31.0 11.4 12.3 13.0 14.3 51.0 14.0 14.7 17.0 20.3 66.0 20.8 23.1 25.9 28.8 98.5
Revenues under collaborative agreements 28.1 58.0 18.2 7.4 5.5 11.3 42.3 4.2 6.2 30.0 100.0 140.4 - - 5.0 - 5.0
Total Revenues 75.3 135.1 42.5 33.3 31.9 39.0 146.7 29.6 33.8 60.5 134.3 258.1 35.3 37.6 45.4 43.3 161.5
Costs & Expenses:
Cost of product revenue 22.7 29.2 7.8 8.3 9.1 8.0 33.2 7.5 7.8 8.8 9.1 33.2 8.7 8.7 8.7 8.7 34.8
R&D 79.7 93.2 40.1 35.5 33.9 41.3 150.8 36.9 38.3 42.0 44.0 161.2 44.0 44.0 40.0 40.0 168.0
SG&A 35.9 40.0 10.8 11.2 11.6 12.2 45.9 12.6 13.1 13.0 13.0 51.7 13.0 13.0 16.0 18.0 60.0
Total Operating Expenses 138.4 162.5 58.7 55.1 54.6 61.6 229.9 57.1 59.2 63.8 66.1 246.2 65.7 65.7 64.7 66.7 262.8
Operating Income (loss) (63.0) (27.5) (16.2) (21.7) (22.7) (22.6) (83.2) (27.5) (25.5) (3.3) 68.2 11.9 (30.4) (28.1) (19.3) (23.4) ( 101.3)
Investment, Interest, & Other Income 0.2 0.4 0.2 0.4 0.3 0.3 1.3 0.3 0.4 0.0 0.1 0.8 0.2 0.1 0.3 0.2 0.8
Interest expense (5.6) (5.2) (3.9) (5.2) (5.3) (5.6) (20.0) (5.4) (5.5) (5.4) (5.4) (21.8) (3.9) (3.9) (3.8) (3.7) (15.3)
Income tax expense 0.3 1.3 (0.4) 1.2 - - - - - - - - -
Net Income (68.4) (32.2) (19.8) (26.9) (28.9) (27.4) ( 103.1) (32.8) (30.6) (8.7) 62.8 (9.4) (34.1) (31.9) (22.8) (26.9) ( 115.8)
Diluted Earnings Per Share ($0.56) ($0.26) ($0.16) ($0.21) ($0.23) ($0.21) ($0.81) ($0.26) ($0.23) ($0.06) $0.47 ($0.07) ($0.25) ($0.24) ($0.17) ($0.20) ($0.86)
Diluted Shares Outstanding 122.7 126.7 127.6 128.0 128.2 128.3 128.0 128.6 134.0 134.2 134.4 132.8 134.6 134.8 135.0 135.1 134.9
Proprietary to Piper Jaffray & Co. October 15, 2017
HALO: Charles Duncan; 212.284.5025
Current disclosure information for this company can be found at:
http://www.piperjaffray.com/researchdisclosures
Recent HALO News
- Halozyme to Participate in Upcoming Investor Conferences • PR Newswire (US) • 05/08/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:09:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:05:55 PM
- HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS • PR Newswire (US) • 05/07/2024 08:01:00 PM
- Mahesh Krishnan Elected to Halozyme's Board of Directors • PR Newswire (US) • 04/25/2024 08:45:00 PM
- Halozyme to Report First Quarter 2024 Financial and Operating Results • PR Newswire (US) • 04/23/2024 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/04/2024 09:13:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 11:49:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/28/2024 09:07:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:12:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:05:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:01:21 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/27/2024 09:08:09 PM
- Halozyme to Participate in Upcoming Investor Conferences • PR Newswire (US) • 02/27/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:59:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:55:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:53:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:49:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/20/2024 09:07:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:03:54 PM
- HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS • PR Newswire (US) • 02/20/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:47:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:41:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:39:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 09:18:09 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM